Natural killer (NK) cells can swiftly kill multiple adjacent cells if these show surface markers
associated with oncogenic transformation. This property, which is unique among immune …

Recent studies have demonstrated the potential of natural killer (NK) cells in immunotherapy
to treat multiple types of cancer. NK cells are innate lymphoid cells that play essential roles …

Background Responses to conventional donor lymphocyte infusion for postallogeneic
hematopoietic cell transplantation (HCT) relapse are typically poor. Natural killer (NK) cell …

Pediatric and young adult (YA) patients with acute myeloid leukemia (AML) who relapse
after allogeneic hematopoietic cell transplantation (HCT) have an extremely poor prognosis …

Chimeric antigen receptors (CARs) are fusion proteins with an extracellular antigen
recognition domain and numerous intracellular signaling domains that have been …

Natural killer (NK) cells can induce an antigen-independent immune response against
malignant cells. A growing number of scientific reports and clinical studies have shown …

The approval of CD19 chimeric antigen receptor (CAR)-engineered T (CAR-T) cell products
in B-cell malignancies represents a breakthrough in CAR-T cell immunotherapy. However …

Adoptive cell therapy has emerged as a powerful treatment for advanced cancers resistant
to conventional agents. Most notable are the remarkable responses seen in patients …

Background The prognosis of patients with recurrent/refractory acute myelogenous leukemia
(AML) remains poor and cell-based immunotherapies hold promise to improve outcomes …

Natural killer (NK) cells are attractive within adoptive transfer settings in cancer
immunotherapy due to their potential for allogeneic use; their alloreactivity is enhanced …